Similar articles

• Cardiovascular safety of canagliflozin.

  Qureshi A, Bandyopadhyay D, Hajra A. Qureshi A, et al. Int J Cardiol. 2017 Nov 15;247:7. doi: 10.1016/j.ijcard.2017.06.128. Int J Cardiol. 2017. PMID: 28916092 No abstract available.
• Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.

  Yale JF, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D, Wajs E, Figueroa K, Jiang J, Law G, Usiskin K, Meininger G; DIA3004 Study Group. Yale JF, et al. Diabetes Obes Metab. 2014 Oct;16(10):1016-27. doi: 10.1111/dom.12348. Epub 2014 Jul 22. Diabetes Obes Metab. 2014. PMID: 24965700 Clinical Trial.
• Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.

  Devineni D, Curtin CR, Polidori D, Gutierrez MJ, Murphy J, Rusch S, Rothenberg PL. Devineni D, et al. J Clin Pharmacol. 2013 Jun;53(6):601-10. doi: 10.1002/jcph.88. Epub 2013 May 14. J Clin Pharmacol. 2013. PMID: 23670707 Clinical Trial.
• A safety evaluation of canagliflozin : a first-in-class treatment for type 2 diabetes.

  Boyle LD, Wilding JP. Boyle LD, et al. Expert Opin Drug Saf. 2014 Nov;13(11):1535-44. doi: 10.1517/14740338.2014.959488. Expert Opin Drug Saf. 2014. PMID: 25340618 Review.
• Canagliflozin for the treatment of type 2 diabetes.

  Babu A. Babu A. Drugs Today (Barc). 2013 Jun;49(6):363-76. doi: 10.1358/dot.2013.49.6.1965099. Drugs Today (Barc). 2013. PMID: 23807940 Review.